Clinical Trials Logo

Disease clinical trials

View clinical trials related to Disease.

Filter by:

NCT ID: NCT04309084 Active, not recruiting - Clinical trials for Cardiovascular Diseases

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Start date: May 12, 2020
Phase: Phase 1
Study type: Interventional

This study will find the maximum tolerated dose (MTD) of CYNK-001 which contain NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given post Autologous Stem Cell Transplant (ASCT). The safety of this treatment will be evaluated, and researchers will want to learn if NK cells will help in treating Multiple Myeloma.

NCT ID: NCT04305535 Recruiting - Crohn Disease Clinical Trials

Impact of an Oligomeric Diet in Intestinal Absorption and Inflammatory Markers in Patients With Crohn Disease

Start date: February 13, 2020
Phase: N/A
Study type: Interventional

This is a randomized, multicenter, translational, triple-blind, clinical trial in patients with Crohn's disease, who will be prescribed an oral nutritional supplement to control symptoms in the acute phase and to recover in the remission phase.

NCT ID: NCT04304417 Completed - Bipolar Disorder Clinical Trials

The Role of Group Identity on the Community Integration of People With Severe Mental Disorder

Start date: February 17, 2020
Phase:
Study type: Observational

This study analyzes which variables enhance or hinder community integration among people with severe mental disorder. Participants will complete a questionnaire to test our hypotheses: - Hypothesis 1: group identification predicts less self-dehumanization and self-stigma, and more empowerment, these in turn predict more community integration. - Hypothesis 2: the relationship between group identification and self-dehumanization and self-stigma is moderated by group value. - Hypothesis 3: when group identification is low, group identification predicts higher community integration, but this relationship is mediated by diagnosis concealment.

NCT ID: NCT04302818 Completed - Depression Clinical Trials

SKOLKONTAKT - Social Skills Training in a School Setting

SKOLKONTAKT
Start date: September 2, 2019
Phase: N/A
Study type: Interventional

The study investigates the behavioral effects of an adapted manual-based social skills training program (SKOLKONTAKT) for the mainstream education plan delivered by school personnel, with pupils (15-20 years) with social-communication needs; either formally diagnosed (i.e. autism spectrum disorders or ADHD) or teacher-reported subclinical difficulties. N=40 are recruited from a community school in the Stockholm area (Sweden).

NCT ID: NCT04301713 Recruiting - Nursing Caries Clinical Trials

Multifactorial Study of the Relationship Between the Conditions of Life and the Incidence of Risk of Falling

Start date: October 1, 2019
Phase:
Study type: Observational

HYPOTHESIS: The incidence of risk of falls is related to the living conditions of elderly people in the community. OBJECTIVES: • To study the relationship between living conditions and the incidence of risk of falls in older adults in the community. SPECIFIC OBJECTIVES: - Describe the socio-characteristics of the elderly group in the community. - Identify the pathologies or health problems that they present. - Evaluate their functional and dependency degree. - Evaluate the risk of falls that each person may have. - Identify the risk factors involved in falls. - Analyze the prevalence of falls that they present. STUDY DESIGN: Descriptive and analytical-statistical study. Administration of the Barthel Index. Administration of the Downton fall risk assessment scale and the Falls Efficacy Scale-International (FES-I). Administration of the Tinetti assessment tool and the Short Physical Performance Battery (SPPB). Evaluation of socio-demographic characteristics, clinical and functional assessment, consumption of drugs, as well as characteristics of the falls of each elderly person in the community. The protocol has been authorized by the Ethics Committee of the Salamanca health area to make the project possible.

NCT ID: NCT04300569 Completed - Clinical trials for Irregular Sleep Wake Rhythm Disorder

A Study to Determine the Signs and Symptoms That Impact Daily Life of Participants With Irregular Sleep-Wake Rhythm Disorder

Start date: July 9, 2020
Phase:
Study type: Observational

The primary purpose of this study is to determine the signs and symptoms of irregular sleep-wake rhythm disorder (ISWRD) that are important to patients and caregivers of patients with Alzheimer's disease dementia (AD-D), AD-D with cerebrovascular disease (CVD), and/or vascular dementia (VaD) and ISWRD, and to draft an instrument or instruments to assess them.

NCT ID: NCT04295837 Completed - Clinical trials for Chronic Conditions, Multiple

A Better Everyday Life Among Persons With Chronic Conditions

ABLE
Start date: December 9, 2019
Phase: N/A
Study type: Interventional

Background: Persons living with chronic conditions often have decreased ability to perform Activities of Daily Living (ADL) tasks, stressing a need to develop and evaluate intervention programs addressing decreased ADL ability. Guided by the British Medical Research Council's guidance (MRC) on how to develop and evaluate complex interventions, the program "A Better everyday LifE" (ABLE), a home-based intervention program, was developed and feasibility tested. The current phase concerns a full-scale evaluation of the ABLE program including evaluation of effectiveness, processes and cost-effectiveness. Material and Methods: The design involves a randomized controlled trial, initiated with an internal pilot. The study will include eighty (n=80) home dwelling persons living with chronic conditions, experiencing problems performing ADL. Participants are randomized to either intervention (ABLE) or control (usual care). Co-primary outcomes are self-reported ADL ability measured using ADL-Questionnaire (ADL-Q) and observed ADL motor ability measured using Assessment of Motor and Process Skills (AMPS). Secondary outcomes are perceived satisfaction with ADL task performance measured using ADL-Q; observed ADL process ability measured using AMPS; and Goal Attainment measured using Goal-Attainment-Scaling (GAS). Data is collected at baseline, post intervention and six months after baseline. Process evaluation data are collected using registration forms and semi-structured qualitative interviews. The economic evaluation will be performed from a health care sector perspective with 6 months follow-up. Costs will be estimated based on micro costing and national registries. Effects will be Quality Adjusted Life Years and changes in AMPS ADL ability.

NCT ID: NCT04295512 Not yet recruiting - Clinical trials for Autism Spectrum Disorder

Adaptation and Implementation of an ASD Executive Functioning Intervention in Children's Mental Health Services

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The purpose of this project is to conduct a feasibility test of an ASD executive functioning intervention adapted for mental health settings, including examining the effectiveness and process of implementing this adapted intervention in community mental health programs.

NCT ID: NCT04294602 Completed - Clinical trials for Temporomandibular Disorder

Efficacy Of Different Types Of Physiotherapy Approaches In Temporomandibular Disorders

Start date: May 15, 2017
Phase: N/A
Study type: Interventional

The aim of this study is to investigate the efficacy of different types of physiotherapy approaches in cases with cervical myofascial painful TMD.

NCT ID: NCT04294290 Completed - Clinical trials for Autism Spectrum Disorder

Open Label Phase I hCT-MSC in Toddlers With Autism Spectrum Disorder

TACT
Start date: February 24, 2021
Phase: Phase 1
Study type: Interventional

This is a single site, prospective study of one intravenous infusion of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) in toddlers with autism spectrum disorder (ASD). Toddlers 18 to 48 months of age with a confirmed diagnosis of ASD will be eligible to participate. Diagnosis will be confirmed at the time of the eligibility visit at the Duke Center for Autism and Brain Development. All participants will receive a single intravenous dose of 2x106/kg hCT-MSC per kilogram at baseline. Assessments will be conducted at baseline and 6 months, with remote follow-up assessments at 12 months.